The biopharmaceutical company Gilead Sciences disclosed this week that Brett Pletcher, its general counsel since 2009, will depart later this year.

Foster City, California-based Gilead, known for developing the antiviral drug remdesivir to combat COVID-19 in 2020, said Pletcher will likely stay on through summer as he assists with finding his replacement and with transition

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]